by The global plasma protease C1-inhibitor treatment market deals with minimizing angioedema attacks in patients with hereditary angioedema (HAE). Plasma protease C1-inhibitor treatment helps regulate plasma kallikrein and blood clotting factors to prevent swelling. C1-inhibitor concentrate helps manage HAE by inhibiting enzymes responsible for edema formation. The market is witnessing strong demand owing to the growing prevalence of HAE globally.
The Global plasma protease C1-inhibitor Treatment Market Demand is estimated to be valued at US$ 6257.99 Bn in 2024 and is expected to exhibit a CAGR of 6.7% over the forecast period 2024 to 2030.
Key Takeaways
Key players:
Key players operating in the plasma protease C1-inhibitor treatment are R&D. Koninklijke Philips N.V., Panasonic Corporation, and Procter & Gamble. Koninklijke Philips N.V focuses on innovative plasma protease C1-inhibitor treatment options to improve patient care.
Growing demand:
The market is witnessing high demand due to the rising prevalence of HAE globally causing recurrent angioedema attacks. According to estimates, about 1 in 10,000-50,000 people have HAE worldwide. This is creating significant demand for effective plasma protease C1-inhibitor treatments.
Global expansion:
Leading players in the market are expanding their global footprint through new product launches, collaborations, and strategic deals. For instance, in 2022, Pharming Group NV launched Ruconest in Japan for aborting HAE attacks. This expansion aided its leadership in the Asia Pacific market.
Market Key Trends
The rising demand for preventive therapies is a key trend in the plasma protease C1-inhibitor treatment market. With growing awareness, patients are increasingly opting for long-term prophylactic therapy using C1-inhibitors instead of short-term treatments to abort attacks. This is beneficial to avoid disabilities and increase quality of life. Consequently, companies are developing additional preventive dosage forms such as subcutaneous injections for better compliance.
Porter’s Analysis
Threat of new entrants: High capital requirements for R&D and testing pose challenges for new companies.
Bargaining power of buyers: Large pharmaceutical companies have greater negotiating power than smaller clients and hospitals.
Bargaining power of suppliers: Proprietary production processes and intellectual property protection give existing suppliers an edge over potential new entrants.
Threat of new substitutes: Ongoing research into new classes of drugs for treatment could reduce demand over time.
Competitive rivalry: Companies invest significant resources in product differentiation and marketing to physicians for market share.
The plasma protease C1-inhibitor treatment market is currently concentrated in North America and Europe due to higher healthcare expenditures and widespread insurance coverage in these regions. In North America alone, the United States accounts for over 60% of market value as patients have good access to approved therapies.
Meanwhile, the Asia Pacific region excluding Japan is poised to be the fastest growing market during the forecast period from 2024 to 2030. Rising incomes, expanding private healthcare infrastructure, and growing disease awareness are enabling more patients in countries such as China and India to access plasma protease C1-inhibitor therapy. China in particular represents a major opportunity as it now has the largest healthcare market worldwide and government policies support the development of domestic biologics industries.
Geographical Regions
The plasma protease C1-inhibitor treatment market is currently concentrated in North America and Europe due to higher healthcare expenditures and widespread insurance coverage in these regions. In North America alone, the United States accounts for over 60% of market value as patients have good access to approved therapies.
Meanwhile, the Asia Pacific region excluding Japan is poised to be the fastest growing market during the forecast period from 2024 to 2030. Rising incomes, expanding private healthcare infrastructure, and growing disease awareness are enabling more patients in countries such as China and India to access plasma protease C1-inhibitor therapy. China in particular represents a major opportunity as it now has the largest healthcare market worldwide and government policies support the development of domestic biologics industries.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
